Company Filing History:
Years Active: 2009-2010
Title: Yeoun Jin Kim: Innovator in Medical Diagnostics
Introduction
Yeoun Jin Kim is a notable inventor based in Germantown, Maryland, whose contributions to the field of medical diagnostics have led to advancements in the diagnosis and treatment of colon and kidney diseases. With a total of two patents to his name, Kim is paving the way for innovative solutions in healthcare.
Latest Patents
Yeoun Jin Kim's latest patents focus on critical disease targets. One of his inventions, titled "Colon disease targets and uses thereof," provides a method for diagnosing and detecting diseases associated with the colon. This invention introduces proteins, fragments, peptides, and nucleic acid molecules that are differentially expressed in colon diseases, collectively referred to as CCAT. It has significant implications for screening agents that modulate CCAT activities and offers methods for treating colon-related diseases.
His second patent, "Kidney disease targets and uses thereof," offers similar diagnostic methods for kidney diseases. This invention highlights proteins, fragments, peptides, and nucleic acid molecules differentially expressed in kidney diseases, known as KCAT. Kim's approach allows for the identification of agents that modulate KCAT activities, thus paving the way for innovative treatment methods in kidney health.
Career Highlights
Currently, Yeoun Jin Kim works at Celera Corporation, where he applies his expertise in biomedicine and diagnostics. His work has garnered recognition within the industry for its focus on improving healthcare outcomes through innovative technology.
Collaborations
Throughout his career, Kim has collaborated with esteemed colleagues such as Steve Ruben and Tao He. These partnerships have facilitated the exchange of ideas and the advancement of research in the medical diagnostics field.
Conclusion
Yeoun Jin Kim continues to be a driving force in medical innovation, with his recent patents showcasing the potential for improved disease diagnosis and treatment. His contributions at Celera Corporation and collaborations with other professionals exemplify the innovative spirit necessary to advance healthcare technologies.